The recommendation is specifically for adult patients with the condition who are eligible for systemic treatment, only if the disease has not responded to at least one systemic immunosuppressant, or if these are not suitable.
The decision from NICE follows a multiple technology appraisal (MTA) and its recommendation simultaneously approves Adtralza, Rinvoq (upadacitinib) and Cibinqo (abrocitinib) for reimbursement following use in NHS England and Wales, which is based upon both cost-effectiveness and a demonstration of positive patient outcomes…
